Keywords: first, launch, delavirdine, usa, pharmacia, upjohn, rescriptor
First Launch Of P&U's Delavirdine In USA
Article | 26 June 1997
Pharmacia & Upjohn's Rescriptor (delavirdine) has been launched in itsfirst market, the USA, and becomes the second non-nucleoside reverse transcriptase inhibitor ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
